Voyager Therapeutics, Inc. (VYGR)
Voyager Therapeutics, Inc. operates as a gene therapy company, concentrating its efforts on developing innovative treatments and pioneering advanced platform technologies. Its leading clinical asset, VY-AADC, is presently undergoing an open-label Phase 1 clinical trial for the management of Parkinson's disease.
Descriptive
Exchange
Industry
Country
Active:none
| Company | Rating | |||||
|---|---|---|---|---|---|---|
| Loading data… | ||||||
Saved screens and full data - with a subscription
Subscribe to save filters and unlock all columns and ratings.
Subscribe - €24.90/mo